tetano
Editor, Senior Moderator
J Clin Immunol
. 2024 Mar 10;44(3):80.
doi: 10.1007/s10875-024-01683-z. Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai
Dongling Shi[SUP] #[/SUP][SUP] 1 2 [/SUP], Jie Chen[SUP] #[/SUP][SUP] 3 [/SUP], Meng Zhao[SUP] #[/SUP][SUP] 4 [/SUP], Yuanjia Tang[SUP] 5 [/SUP], Chen Zhao[SUP] 2 [/SUP], Yinpeng Jin[SUP] 6 [/SUP], Di Tian[SUP] 2 [/SUP], Yixin Liao[SUP] 2 [/SUP], Xuebi Wang[SUP] 1 2 [/SUP], Wei Wang[SUP] 2 [/SUP], Xiaohong Fan[SUP] 7 [/SUP], Zhigang Yi[SUP] 8 9 [/SUP], Xiaohua Chen[SUP] 10 [/SUP], Yun Ling[SUP] 11 12 [/SUP]
Affiliations
Objective: We sought to explore the prevalence of type I interferon-neutralizing antibodies in a Chinese cohort and its clinical implications during the Omicron variant wave of SARS-CoV-2.
Methods: Type I interferon (IFN) autoantibodies possessing neutralizing capabilities were identified using luciferase assays. The capacity of the autoantibodies for in vitro interference with antiviral activity of IFN was assessed by using a SARS-CoV-2 replicon system. An analysis of the demographic and clinical profiles of patients exhibiting neutralizing antibodies was also conducted.
Results: In this cohort, 11.8% of severe/critical cases exhibited the existence of type I IFN-neutralizing antibodies, specifically targeting IFN-α2, IFN-ω, or both, with an elderly male patient tendency. Notably, these antibodies exerted a pronounced inhibitory effect on the antiviral activity of IFN against SARS-CoV-2 under controlled in vitro conditions. Furthermore, a noteworthy correlation was discerned between the presence of these neutralizing antibodies and critical clinical parameters, including C-reactive protein (CRP) levels, D-dimer levels, and lymphocyte counts.
Conclusion: The presence of type I IFN-neutralizing antibodies is a pervasive risk factor for severe/critical COVID-19 in the Chinese population.
Keywords: COVID-19; IFN-α2; IFN-ω; Neutralizing antibodies; Type I interferons.
. 2024 Mar 10;44(3):80.
doi: 10.1007/s10875-024-01683-z. Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai
Dongling Shi[SUP] #[/SUP][SUP] 1 2 [/SUP], Jie Chen[SUP] #[/SUP][SUP] 3 [/SUP], Meng Zhao[SUP] #[/SUP][SUP] 4 [/SUP], Yuanjia Tang[SUP] 5 [/SUP], Chen Zhao[SUP] 2 [/SUP], Yinpeng Jin[SUP] 6 [/SUP], Di Tian[SUP] 2 [/SUP], Yixin Liao[SUP] 2 [/SUP], Xuebi Wang[SUP] 1 2 [/SUP], Wei Wang[SUP] 2 [/SUP], Xiaohong Fan[SUP] 7 [/SUP], Zhigang Yi[SUP] 8 9 [/SUP], Xiaohua Chen[SUP] 10 [/SUP], Yun Ling[SUP] 11 12 [/SUP]
Affiliations
- PMID: 38462559
- PMCID: PMC10925575
- DOI: 10.1007/s10875-024-01683-z
Objective: We sought to explore the prevalence of type I interferon-neutralizing antibodies in a Chinese cohort and its clinical implications during the Omicron variant wave of SARS-CoV-2.
Methods: Type I interferon (IFN) autoantibodies possessing neutralizing capabilities were identified using luciferase assays. The capacity of the autoantibodies for in vitro interference with antiviral activity of IFN was assessed by using a SARS-CoV-2 replicon system. An analysis of the demographic and clinical profiles of patients exhibiting neutralizing antibodies was also conducted.
Results: In this cohort, 11.8% of severe/critical cases exhibited the existence of type I IFN-neutralizing antibodies, specifically targeting IFN-α2, IFN-ω, or both, with an elderly male patient tendency. Notably, these antibodies exerted a pronounced inhibitory effect on the antiviral activity of IFN against SARS-CoV-2 under controlled in vitro conditions. Furthermore, a noteworthy correlation was discerned between the presence of these neutralizing antibodies and critical clinical parameters, including C-reactive protein (CRP) levels, D-dimer levels, and lymphocyte counts.
Conclusion: The presence of type I IFN-neutralizing antibodies is a pervasive risk factor for severe/critical COVID-19 in the Chinese population.
Keywords: COVID-19; IFN-α2; IFN-ω; Neutralizing antibodies; Type I interferons.